Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948670 · ClinicalTrials.gov registry record · NA
Participant Satisfaction With the BUILD Mobile Application
A NA study, sponsored by Woebot Health.
- Completed
- Registry status
- NA
- Development phase
- 175
- Enrollment target
NCT05948670: Completed NA study, sponsored by Woebot Health.
NCT05948670 is a NA study that has completed, run by Woebot Health. The registered enrollment target is 175 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05948670, a NA study, has completed, sponsored by Woebot Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study explores user satisfaction with the BUILD mobile application.
Primary Outcome
The CSQ-8 is an 8-item measure used to assess client's satisfaction with treatment.Total scores range from 8-32, with high scores indicating greater satisfaction with the treatment.
Interventions
- DEVICE DISC-MVP
- DEVICE DISC-CON
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2023-11-15 |
| Phase | NA |
What the finished NCT05948670 record still lists
NCT05948670 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which DISC-MVP is the first listed.
NCT05948670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05948670 about?
NCT05948670 is a clinical study titled "Participant Satisfaction With the BUILD Mobile Application". This study explores user satisfaction with the BUILD mobile application.
What is the current status of trial NCT05948670?
This trial is currently completed. It is a NA study. The enrollment target is 175 participants. The study started on 2023-10-04. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT05948670?
The interventions under investigation include: DISC-MVP (DEVICE), DISC-CON (DEVICE).
Who is sponsoring clinical trial NCT05948670?
This trial is sponsored by Woebot Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05948670's enrollment target sits among peer trials
175 610th of 2000 higher than 1,391 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI